PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33080900-0	2020	In silico Investigation on the Inhibiting Role of Nicotine/Caffeine by Blocking the S Protein of SARS-CoV-2 Versus ACE2 Receptor.	Nicotine	50-58	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	84-85	
33080900-2	2020	The simulations reveal the efficient blocking of ACE2 by caffeine and nicotine in the exposure to the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).	Nicotine	70-78	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	102-107	
33080900-2	2020	The simulations reveal the efficient blocking of ACE2 by caffeine and nicotine in the exposure to the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).	Nicotine	70-78	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	109-110	
33080900-3	2020	We have selected the two most important active sites of ACE2-S protein, i.e., 6LZG and 6VW1, which are critically responsible in the interaction of S protein to the receptor and thus, we investigated their interaction with nicotine and caffeine through MD simulations.	Nicotine	223-231	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	61-62	
33080900-5	2020	Our results reveal that caffeine or nicotine in a specific molar ratio to 6LZG shows a very strong interaction and indicate that caffeine is more efficient in the interaction with 6LZG and further blocking of this site against S protein binding.	Nicotine	36-44	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	227-228	
33080900-6	2020	Further, we investigated the interaction of ACE2 receptor- S protein with nicotine or caffeine when mixed with candidate or approved antiviral drugs for SARS-CoV-2 therapy.	Nicotine	74-82	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	59-60